Mikhail Blagosklonny: Scientist and Expert on Oncology

Mikhail attended the First Pavlov State Medical University of St. Peterburg where he graduated with a Master’s degree in internal medicine and a Ph.D. in experimental medicine. He joined the New York Medical College in Valhalla as an associate professor of medicine on impactjournals.com. Mikhail later became a senior scientist at Ordway Research Institute and worked here for seven years. Mikhail joined the Roswell Park Cancer Institute as a professor of oncology in 2009. His work at the Institute varies from teaching to conducting research in the field of oncology.

Mikhail Blagosklonny has written around 270 papers. They have gotten nearly 30,000 citations giving him an h-index of 83. Mikhail’s research over the years has revolved around signal transduction, molecular biology, oncogenes, and tumor suppressors. The unique and new strategies that he has developed over the years have established him as one of the top most researchers on cancer and aging therapeutics.

One of his famous papers is on the role of TOR signaling in aging. Blagosklonny says that the overdevelopment of cells causes cancer and aging and that cancer is a sign of aging. This is why he proposed the use of rapamycin on tandfonline.com as an anti-ageing drug. He had demonstrated in one of his earlier articles that rapamycin slows down cellular senescence which is deterioration with age.

Mikhail is the editor-in-chief of Aging and its founding editor at http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=3740. He is one of the editors-in-chief of Oncotarget and Oncoscience. Oncotarget is a medical journal on oncology published by Impact Journals. The journal is open access, peer reviewed, and released on a weekly basis. The journal among the most important journals in cancer research. It has helped to encourage collaboration between scientists. This is because it is free and is released online. It can be accessed by anyone regardless of location. He is an editor of Cell Death & Differentiation, Cancer Biology & Therapy, and Autophagy.

1 thought on “Mikhail Blagosklonny: Scientist and Expert on Oncology”

  1. This means that rapamycin could be used as an anti-aging drug since aging is just the deterioration of cells because they do not stop developing. The drug ceases to be beneficial after a period of time in one’s life. It serves as a cool thing for http://www.rushessaya.com/ to do and to become such a wonderful achievement for them all too.

Leave a Reply

Your email address will not be published. Required fields are marked *